Although I don't disagree with being a bit disappointed
Although I don't disagree with being a bit disappointed about the EUA. I do disagree with your sentiment about Nader pumping the call. I posted something same day of the CC PR saying I thought the call wouldn't be what we wanted because it led with the bla meeting very successful, and covid updates only listed as being on the call. Also mentioned the cheerleaders that NP likes to bring in to overshadow less than stellar news to remind us all how well leronlimab works. Not tooting my horn, just been around for awhile.
So not surprised, but was hoping for more. NPs tone was not his usual pulpit tone. Sounded tired/disappointed to me and I think that got the best of him when he had no love for the people pressing for timelines. The one thing I do remember is they will be taking advantage of that 30 day thing by the FDA to help make sure the bla is what they want. So for sure we won't be refiling right away. Might be a month.
What I did like. Dr recknor or agresti? I forget which one said they are cautiously optimistic on the S/C trial based on what they are seeing so far. Boots on the ground eyeball evidence is good to hear though the data needs to prove it. Nash moving forward. Blood brain barrier, and the fact that NPs Mother in law is still alive almost 1 year later(stroke story interesting, but not putting too much emphasis on that) Uplisting review hopefully completed next week, although qualifying might be a tough sell. So I'll keep expectations low, I'm guessing MMs comments may mean if they have to raise money to qualify, it's gonna be awhile cuz they don't want to do it at low prices.
Happy day to all it's gonna be a doozy for the stock price today so buckle in and throw your hands up, or if you decide to jump off the ride, good luck on future endeavors!
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...
Continue Reading
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
div>